ARAY:NSD-Accuray Incorporated (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.94

Change

-0.04 (-2.02)%

Market Cap

USD 0.19B

Volume

0.40M

Avg Analyst Target

USD 7.25 (+273.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ARAY Stock Forecast & Price:
Based on the Accuray Incorporated stock forecasts from 2 analysts, the average analyst target price for Accuray Incorporated is USD 7.25 over the next 12 months. Accuray Incorporated’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Accuray Incorporated is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Accuray Incorporated’s stock price was USD 1.94. Accuray Incorporated’s stock price has changed by -7.62% over the past week, -6.73% over the past month and -63.53% over the last year.

About Accuray Incorporated (ARAY:NSD)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a ro ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+4.76 (+4.04%)

USD45.54B 262.02 104.59
PODD Insulet Corporation

-1.55 (-0.51%)

USD21.17B 1,270.38 182.17
ABMD ABIOMED Inc

+2.96 (+0.78%)

USD17.04B 64.80 57.47
ALGN Align Technology Inc

+3.13 (+1.67%)

USD14.78B 28.00 16.65
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.64 (+0.97%)

USD9.78B 36.52 19.83
SWAV Shockwave Medical Inc

+5.31 (+2.27%)

USD8.41B 98.60 91.46
IART Integra LifeSciences Holdings

+0.89 (+1.60%)

USD4.57B 26.97 16.00
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
NARI Inari Medical Inc

+0.49 (+0.71%)

USD3.82B N/A -287.45

ETFs Containing ARAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.33% 43% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.33% 43% F 28% F
Trailing 12 Months  
Capital Gain -61.58% 45% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.58% 45% F 28% F
Trailing 5 Years  
Capital Gain -60.41% 38% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.41% 38% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 1.10% 53% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.10% 53% F 56% F
Risk Return Profile  
Volatility (Standard Deviation) 58.42% 39% F 21% F
Risk Adjusted Return 1.88% 52% F 48% F
Market Capitalization 0.19B 58% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.60 28% F 13% F
Price/Book Ratio 4.09 37% F 22% F
Price / Cash Flow Ratio -77.37 98% A+ 82% B-
EV/EBITDA 44.53 6% F 4% F
Management Effectiveness  
Return on Equity -21.06% 69% D+ 44% F
Return on Invested Capital 2.02% 79% C+ 62% D-
Return on Assets 0.47% 85% B 60% D-
Debt to Equity Ratio 323.20% 3% F 6% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 14.00 6% F 6% F
Short Percent 5.47% 27% F 28% F
Beta 1.62 21% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector